• Something wrong with this record ?

Comparison of cationic propyl gallate and adenosine diphosphate for the measurement of aspirin effectivity with optical aggregometry

Z Motovska, Z Sujanova, S Wimmerova, J Ardo, M Skrakova, P Widimsky

. 2007 ; 150 (4) : 246-252.

Language English Country United States

Document type Comparative Study, Controlled Clinical Trial

E-resources Online

NLK ScienceDirect (archiv) from 2006-01-01 to 2009-12-31

To compare the newer inductor of platelet aggregation cationic propyl gallate (CPG) with adenosine diphosphate (ADP) for the examination of aspirin (ASA) effectivity with optical aggregometry. In total,116 patients were prospectively enrolled with a stable cardiovascular disease, taking ASA 100 mg/day for >or=1 month. The control group consisted of 62 healthy volunteers. A platelet aggregation was investigated by optical aggregometry (aggregometer LASER 4x; BIO ART, Sint-Katelijne-Waver, Belgium). CPG and ADP were added as aggregating agents. The measured parameters were CPG-slope (%/min) and ADP max (%). Using the CPG-slope values from the control group, the CPG-slope cut-off value was determined to define a laboratory ASA-noneffectively treated patient. The values from control group followed a normal distribution (Shapiro-Wilk test). We calculated the cut-off value using the 1-tailed 95% confidence interval. The CPG-slope cut-off value was 79 %/min for an ASA-effectively treated patient. We marked the patients as laboratory ASA-noneffective treated when the CPG-slope was >79%/min. In the same way we defined the cut-off value for ADP-max. We identified the aspirin treatment as ineffective when the value of ADP-max was >62%. The values of CPG-slope and ADP-max were in close correlation in the group of patients treated with aspirin with a highly significant correlation index (r=0.671, P<0.001). By CPG-induced optical aggregation, 33,6% were ASA-noneffectively treated patients. When using both inductors, the proportion of ASA-noneffectively treated patients was 25%. Using both tests, 72.4% of patients were equally divided. ASA-noneffectively treated patients were commonly more obese (46.2%), had hypertension (94.9%) and hypercholesterolemia (73.7%), and were less commonly treated with statins (30.8%) than the aspirin effectively treated patients (42%, 88.2%, 59.2%, and 42.1%, respectively). The detected differences were not statistically significant. Cationic propyl gallate is an optimal inductor for optical aggregometry to monitor laboratory effectiveness of aspirin therapy in routine clinical pratice. The determined high prevalence of laboratory aspirin ineffectiveness highlights the clinical importance of the problem. This study brings attention to the importance of controlling cardiovascular risk factors.

000      
04604naa 2200517 a 4500
001      
bmc10013268
003      
CZ-PrNML
005      
20140221150417.0
008      
100602s2007 xxu e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Moťovská, Zuzana $7 xx0104795
245    10
$a Comparison of cationic propyl gallate and adenosine diphosphate for the measurement of aspirin effectivity with optical aggregometry / $c Z Motovska, Z Sujanova, S Wimmerova, J Ardo, M Skrakova, P Widimsky
314    __
$a Cardiocentre, Third Medical School Charles University, Prague, Czech Republic, and the Clinic of Haematologie, University Hospital, Bratislava, Slovak Republic. zuzana.motovska@iex.cz
520    9_
$a To compare the newer inductor of platelet aggregation cationic propyl gallate (CPG) with adenosine diphosphate (ADP) for the examination of aspirin (ASA) effectivity with optical aggregometry. In total,116 patients were prospectively enrolled with a stable cardiovascular disease, taking ASA 100 mg/day for >or=1 month. The control group consisted of 62 healthy volunteers. A platelet aggregation was investigated by optical aggregometry (aggregometer LASER 4x; BIO ART, Sint-Katelijne-Waver, Belgium). CPG and ADP were added as aggregating agents. The measured parameters were CPG-slope (%/min) and ADP max (%). Using the CPG-slope values from the control group, the CPG-slope cut-off value was determined to define a laboratory ASA-noneffectively treated patient. The values from control group followed a normal distribution (Shapiro-Wilk test). We calculated the cut-off value using the 1-tailed 95% confidence interval. The CPG-slope cut-off value was 79 %/min for an ASA-effectively treated patient. We marked the patients as laboratory ASA-noneffective treated when the CPG-slope was >79%/min. In the same way we defined the cut-off value for ADP-max. We identified the aspirin treatment as ineffective when the value of ADP-max was >62%. The values of CPG-slope and ADP-max were in close correlation in the group of patients treated with aspirin with a highly significant correlation index (r=0.671, P<0.001). By CPG-induced optical aggregation, 33,6% were ASA-noneffectively treated patients. When using both inductors, the proportion of ASA-noneffectively treated patients was 25%. Using both tests, 72.4% of patients were equally divided. ASA-noneffectively treated patients were commonly more obese (46.2%), had hypertension (94.9%) and hypercholesterolemia (73.7%), and were less commonly treated with statins (30.8%) than the aspirin effectively treated patients (42%, 88.2%, 59.2%, and 42.1%, respectively). The detected differences were not statistically significant. Cationic propyl gallate is an optimal inductor for optical aggregometry to monitor laboratory effectiveness of aspirin therapy in routine clinical pratice. The determined high prevalence of laboratory aspirin ineffectiveness highlights the clinical importance of the problem. This study brings attention to the importance of controlling cardiovascular risk factors.
650    _2
$a adenosindifosfát $x farmakologie $7 D000244
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a Aspirin $x terapeutické užití $7 D001241
650    _2
$a kardiovaskulární nemoci $x farmakoterapie $x krev $x prevence a kontrola $7 D002318
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a kationty $x farmakologie $7 D002412
650    _2
$a léková rezistence $7 D004351
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a faktor aktivující destičky $x účinky léků $7 D010972
650    _2
$a inhibitory agregace trombocytů $x terapeutické užití $7 D010975
650    _2
$a vyšetření funkce trombocytů $x metody $x normy $x přístrojové vybavení $7 D010979
650    _2
$a trombocytový glykoproteinový komplex IIb-IIIa $x metabolismus $7 D019039
650    _2
$a propylgalan $x farmakologie $7 D011435
650    _2
$a senzitivita a specificita $7 D012680
650    _2
$a financování organizované $7 D005381
650    _2
$a techniky in vitro $7 D066298
655    _2
$a srovnávací studie $7 D003160
655    _2
$a klinické zkoušky kontrolované $7 D018848
700    1_
$a Šujanová, Zdenka. $7 xx0248979
700    1#
$a Wimmerová, Soňa $7 xx0234999
700    1_
$a Ardó, Ján. $7 _AN058246
700    1_
$a Skraková, Marcela, $d 1954- $7 xx0137989
700    1_
$a Widimský, Petr, $d 1954- $7 jn20000402682
773    0_
$t Translational Research: The Journal Of Laboratory & Clinical Medicine $w MED00152122 $g Roč. 150, č. 4 (2007), s. 246-252 $x 1931-5244
910    __
$a ABA008 $b x $y 7 $z 0
990    __
$a 20110222134556 $b ABA008
991    __
$a 20140221151226 $b ABA008
999    __
$a ok $b bmc $g 749135 $s 612763
BAS    __
$a 3
BMC    __
$a 2007 $b 150 $c 4 $d 246-252 $i 1931-5244 $m Translational research $n Transl Res $x MED00152122
LZP    __
$a 2010-B2/ipme

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...